IGI Logo

Below are Quote on Jubilant Ingrevia Ltd -1QFY22 - Result Update by Mr. Amarjeet Maurya, AVP - Mid Caps, Angel Broking Ltd

Jubilant Ingrevia Ltd (JIL) 1QFY2022 results outperformed the estimates. The top-line grew by ~55% YoY to Rs1,145cr on the back of robust growth in volume and prices. On segment wise,  Speciality Chemicals revenue grew by ~18% yoy, Nutrition and Health Solutions revenue grew by ~13% yoy and Life Sciences Chemical revenue grew by ~103% yoy.On the EBITDA front, the company has reported ~Rs287cr, grew by 126% on account of strong performance of Speciality Chemical & Life Sciences chemical segment led by favorable market conditions. JIL reported EBITDA margin improvement (up by 783bp YoY to 25.1%). The reported net profit grew by ~220% YoY to Rs168cr, on account of strong sales growth and operating performance. Currently we are positive on the stock.

Above views are of the author and not of the website kindly read disclaimer